Developer docs
API playgroundTry for free, no card

Search company profiles

Impulse Biomedical

Full company profile

uuid0003cgr

Namestring
Impulse Biomedical
Legal namestring
Impulse Biomedical
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Impulse Biomedical is a South African medical device developer founded in 2017 by biomedical engineers Giancarlo Beukes and Gokul Nair while completing Master's degrees at the University of Cape Town. The company designs, manufactures, and is commercializing two flagship products: the ZiBiPen, a reloadable epinephrine auto-injector for emergency anaphylaxis treatment featuring a cartridge-based architecture that replaces only the drug cartridge rather than the full device, and the Easy Squeezy, an ergonomic reusable sleeve compatible with standard metered-dose inhalers (Asthavent, Ventolin, Ciclovent) that reduces activation force by approximately 80%. Both products are patented in the US, Europe, and Africa, and the company operates under ISO 13485 certification with a SAHPRA Manufacturer's License in South Africa and CE marking on the Easy Squeezy for European market access.

The business model is hardware sales of proprietary medical devices, with the ZiBiPen architecture generating recurring revenue through replacement cartridge sales and the Easy Squeezy sold as a reusable accessory. The company is explicitly pre-revenue, having secured approximately $1.6 million in disclosed venture funding across rounds led by Launch Africa, Futuregrowth Asset Management, the University Technology Fund, Futuregrowth Development Equity Fund, and ANZA Capital. Distribution is being built through pharmacy channels in South Africa, the Maryland Global Gateway Soft Landing Program and The LaunchPort medtech accelerator in Baltimore for US market entry, and direct partnership/inquiry-based enterprise sales.

Target customer segments include children with asthma (5-12 years), elderly patients with reduced hand strength, anaphylaxis and allergy sufferers requiring emergency epinephrine, and underserved populations in developing markets facing affordability barriers. The company's strategic positioning emphasizes patient-led design, affordability, and accessibility, with quantified claims of 88% cost savings over a 5-year period for ZiBiPen versus traditional auto-injectors, 12x lower injury risk, and 26% improvement in asthma control metrics for Easy Squeezy users. Headcount is reported at 1-10 employees, and the team is led by the two co-founders with support from a General Manager, Product Managers, Engineering staff, Quality Lead, Design Lead, and Regulatory & QA Manager.

Short descriptiontext

Impulse Biomedical is a Cape Town-based medical device company developing the ZiBiPen reloadable epinephrine auto-injector for anaphylaxis and the Easy Squeezy asthma inhaler assist sleeve, targeting children, elderly patients, and underserved populations in emerging markets with patented, ISO 13485-certified, pre-commercial products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCape Town, South Africa
HQ citystring
Cape Town
HQ countrystring
South Africa
HQ regionstring
Africa
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
asthma inhaler accessories, epinephrine auto-injectors, reloadable medical devices, anaphylaxis treatment devices, medical device manufacturing
Industry2 codes
PRIMARYHLAHAIAB
Auto-Injectors (Disposable & Reusable)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of proprietary medical devices including the ZiBiPen reloadable autoinjector and Easy Squeezy asthma assist device. The reloadable design of ZiBiPen creates ongoing revenue through replacement cartridge sales while Easy Squeezy is offered as a reusable device. Company is currently pre-revenue and raising funds to scale manufacturing and secure regulatory approvals.

impulsebiomed.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Impulse Biomedical designs, develops, and manufactures proprietary medical devices for asthma and allergy management. Its core products are the ZiBiPen, a patented reloadable epinephrine auto-injector for emergency anaphylaxis treatment that reduces cost by replacing only the drug cartridge, and the Easy Squeezy, an ergonomic reusable sleeve that fits over standard metered-dose inhalers to reduce activation force by 80%, enabling independent use by children and elderly patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 80% reduction in activation force for asthma inhalers (Easy Squeezy)
+5 more records
Product overview1 text field

Impulse Biomedical is a medical device development company offering two core products: Easy Squeezy (an asthma inhaler accessibility accessory sleeve) and ZiBiPen (a reloadable epinephrine auto-injector). Both devices are designed to improve accessibility and affordability of life-saving medical treatments, particularly for children, elderly, and patients in developing regions. The company operates from South Africa with expansion into the US market via the Maryland Global Gateway program at The LaunchPort in Baltimore.

Product and service2 records
1Easy Squeezy
CategoryMedical device / Asthma inhaler accessory
Description

An ergonomic reusable sleeve that fits over standard metered-dose asthma inhalers (compatible with Asthavent, Ventolin, and Ciclovent brands), reducing activation force by 80% (4x easier). Includes a built-in dose counter and child-friendly decorative characters to reduce stigma. Clinically proven to improve asthma control by 26% and lower treatment age from 12 to 5 years. Designed for children, elderly patients, and anyone with limited finger strength.

2ZiBiPen
CategoryMedical device / Emergency epinephrine auto-injector
Description

A reloadable adrenaline (epinephrine) auto-injector for emergency treatment of life-threatening anaphylaxis. Features a user-friendly design with reloadable cartridge (replacing only the drug cartridge rather than the entire device), safety cap, clear medication window, adjustable needle length, and dosage indicator. Clinically validated with pharmacokinetic trials confirming drug delivery effectiveness comparable to leading competitors. Offers 88% cost savings over a 5-year period versus traditional auto-injectors and 12x lower injury risk.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Maryland Department of Commerce administers the Global Gateway Soft Landing Program that officially welcomed Impulse Biomedical. The program provides international companies support and resources to establish US presence, including access to facilities, capital, and partner advisors with industry knowledge. The state announced Impulse Biomed's medtech sector win at SelectUSA Investment Summit.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

The LaunchPort is a Medtech manufacturing accelerator in Baltimore, MD where Impulse officially took up residence as part of its global expansion. The facility offers regulatory expertise, manufacturing infrastructure, and commercial partnership opportunities essential for US market entry. Impulse will explore manufacturing and sterilization partnerships through this accelerator.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Both ZiBiPen and Easy Squeezy were developed while founders Gokul Nair and Giancarlo Beukes completed Master's degrees in Biomedical Engineering at UCT. The Easy Squeezy was developed in collaboration with Dr Michael Levin, Head of Division of Asthma and Allergy at Red Cross Children's Hospital. Company maintains ongoing partnerships with UCT Med-Tech and University Tech Fund.

4Allergy Foundation of South Africa
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner organization supporting allergy awareness and treatment access in South Africa, listed among collaborative successes on company website.

impulsebiomed.com
5UCT Med-Tech
Strategic tierMinorTypeStrategic or Co-development Partner
Description

University of Cape Town medical technology initiative supporting biomedical innovation and commercialization, listed among collaborative successes.

impulsebiomed.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AstraZeneca markets major respiratory brands (Symbicort, Breztri) and is investing heavily in respiratory biologics. Comparable as a broad respiratory incumbent whose inhaler portfolio is compatible with the Easy Squeezy device.

TypeBroad incumbent
Description

Teva markets a generic EpiPen competitor as well as a broad respiratory portfolio (including ProAir inhalers compatible with Easy Squeezy). Operates in both of Impulse's core categories at scale with established distribution and regulatory infrastructure.

TypeDirect peer
Description

Viatris markets the EpiPen, the dominant single-use epinephrine auto-injector that Impulse's ZiBiPen directly competes against. Comparable on indication (anaphylaxis), patient population, and delivery modality, though Viatris operates at vastly greater scale and with a single-use (non-reloadable) architecture.

TypeDirect peer
Description

Kaleo manufactures AUVI-Q, a competing epinephrine auto-injector with voice-guided instructions. Direct competitor to ZiBiPen in the US anaphylaxis market, with comparable device form factor but differentiated by features (voice guidance vs. reloadable cartridge).

TypeBroad incumbent
Description

GSK is a global leader in respiratory medicine (Ventolin, Advair, Trelegy) and would be a key inhaler manufacturer whose products are compatible with the Easy Squeezy. As a broad incumbent, GSK dwarfs Impulse in R&D and commercial reach, but its inhaler franchise is the natural target market for the Easy Squeezy sleeve.

TypeDirect peer
Description

MannKind develops inhaled drug delivery systems (Afrezza inhaler) and has a deep focus on innovative, patient-friendly inhaler technology. Comparable as a smaller specialty drug delivery company focused on inhalers, with similar disruptive positioning against large incumbents.

TypeEmerging player
Description

Insulet's Omnipod is a reloadable, wearable drug delivery device (for insulin) that shares Impulse's architectural philosophy of reloadable cartridges replacing single-use devices. Comparable on the reloadable consumable model that anchors Impulse's value proposition.

TypeOthers
Description

Halozyme licenses its ENHANZE drug delivery platform to pharma partners for subcutaneous delivery of biologics. Comparable as an enabling drug delivery technology company in the broader medical device space, though focused on biologic formulations rather than emergency rescue injectors.

TypeDirect peer
Description

Amphastar manufactures generic epinephrine auto-injectors (Symjepi) and competes with both EpiPen and ZiBiPen in the anaphylaxis space. Direct competitor on product category and indication, with focus on affordability similar to Impulse's positioning.

TypeEmerging player
Description

ResMed's Propeller Health business offers digital inhaler sensors and companion software to improve asthma adherence and technique—addressing overlapping problems (poor inhaler technique in children and adults) as Impulse's Easy Squeezy, but via digital rather than mechanical intervention.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Impulse Biomedical

Medical Devicesimpulsebiomed.com

Impulse Biomedical is a Cape Town-based medical device company developing the ZiBiPen reloadable epinephrine auto-injector for anaphylaxis and the Easy Squeezy asthma inhaler assist sleeve, targeting children, elderly patients, and underserved populations in emerging markets with patented, ISO 13485-certified, pre-commercial products.

What Impulse Biomedical does

Impulse Biomedical is a South African medical device developer founded in 2017 by biomedical engineers Giancarlo Beukes and Gokul Nair while completing Master's degrees at the University of Cape Town. The company designs, manufactures, and is commercializing two flagship products: the ZiBiPen, a reloadable epinephrine auto-injector for emergency anaphylaxis treatment featuring a cartridge-based architecture that replaces only the drug cartridge rather than the full device, and the Easy Squeezy, an ergonomic reusable sleeve compatible with standard metered-dose inhalers (Asthavent, Ventolin, Ciclovent) that reduces activation force by approximately 80%. Both products are patented in the US, Europe, and Africa, and the company operates under ISO 13485 certification with a SAHPRA Manufacturer's License in South Africa and CE marking on the Easy Squeezy for European market access.

The business model is hardware sales of proprietary medical devices, with the ZiBiPen architecture generating recurring revenue through replacement cartridge sales and the Easy Squeezy sold as a reusable accessory. The company is explicitly pre-revenue, having secured approximately $1.6 million in disclosed venture funding across rounds led by Launch Africa, Futuregrowth Asset Management, the University Technology Fund, Futuregrowth Development Equity Fund, and ANZA Capital. Distribution is being built through pharmacy channels in South Africa, the Maryland Global Gateway Soft Landing Program and The LaunchPort medtech accelerator in Baltimore for US market entry, and direct partnership/inquiry-based enterprise sales.

Target customer segments include children with asthma (5-12 years), elderly patients with reduced hand strength, anaphylaxis and allergy sufferers requiring emergency epinephrine, and underserved populations in developing markets facing affordability barriers. The company's strategic positioning emphasizes patient-led design, affordability, and accessibility, with quantified claims of 88% cost savings over a 5-year period for ZiBiPen versus traditional auto-injectors, 12x lower injury risk, and 26% improvement in asthma control metrics for Easy Squeezy users. Headcount is reported at 1-10 employees, and the team is led by the two co-founders with support from a General Manager, Product Managers, Engineering staff, Quality Lead, Design Lead, and Regulatory & QA Manager.

Impulse Biomedical firmographics

Firmographics
Name
Impulse Biomedical
Legal name
Impulse Biomedical
Website
https://impulsebiomed.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Impulse Biomedical is a Cape Town-based medical device company developing the ZiBiPen reloadable epinephrine auto-injector for anaphylaxis and the Easy Squeezy asthma inhaler assist sleeve, targeting children, elderly patients, and underserved populations in emerging markets with patented, ISO 13485-certified, pre-commercial products.
Ownership category
akta.pro rank

Impulse Biomedical industry classification

Industry
Product category
Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAB
Auto-Injectors (Disposable & Reusable)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Asthma inhaler accessories
  • Epinephrine auto-injectors
  • Reloadable medical devices
  • Anaphylaxis treatment devices
  • Medical device manufacturing

Where Impulse Biomedical is headquartered

Location

Headquarters

HQ city
Cape Town
HQ country
South Africa
HQ region
Africa

Offices2 records

Markets served

Impulse Biomedical business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of proprietary medical devices including the ZiBiPen reloadable autoinjector and Easy Squeezy asthma assist device. The reloadable design of ZiBiPen creates ongoing revenue through replacement cartridge sales while Easy Squeezy is offered as a reusable device. Company is currently pre-revenue and raising funds to scale manufacturing and secure regulatory approvals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Impulse Biomedical product offering

Product offering

Core offering

Impulse Biomedical designs, develops, and manufactures proprietary medical devices for asthma and allergy management. Its core products are the ZiBiPen, a patented reloadable epinephrine auto-injector for emergency anaphylaxis treatment that reduces cost by replacing only the drug cartridge, and the Easy Squeezy, an ergonomic reusable sleeve that fits over standard metered-dose inhalers to reduce activation force by 80%, enabling independent use by children and elderly patients.

Product overview

Impulse Biomedical is a medical device development company offering two core products: Easy Squeezy (an asthma inhaler accessibility accessory sleeve) and ZiBiPen (a reloadable epinephrine auto-injector). Both devices are designed to improve accessibility and affordability of life-saving medical treatments, particularly for children, elderly, and patients in developing regions. The company operates from South Africa with expansion into the US market via the Maryland Global Gateway program at The LaunchPort in Baltimore.

Differentiator

Problem solved

Functional benefit

Products and services

  • Easy Squeezy An ergonomic reusable sleeve that fits over standard metered-dose asthma inhalers (compatible with Asthavent, Ventolin, and Ciclovent brands), reducing activation force by 80% (4x easier). Includes a built-in dose counter and child-friendly decorative characters to reduce stigma. Clinically proven to improve asthma control by 26% and lower treatment age from 12 to 5 years. Designed for children, elderly patients, and anyone with limited finger strength.
  • ZiBiPen A reloadable adrenaline (epinephrine) auto-injector for emergency treatment of life-threatening anaphylaxis. Features a user-friendly design with reloadable cartridge (replacing only the drug cartridge rather than the entire device), safety cap, clear medication window, adjustable needle length, and dosage indicator. Clinically validated with pharmacokinetic trials confirming drug delivery effectiveness comparable to leading competitors. Offers 88% cost savings over a 5-year period versus traditional auto-injectors and 12x lower injury risk.

Quantifiable outcome

  • 80% reduction in activation force for asthma inhalers (Easy Squeezy)
  • +5 more outcomes

Companies that use Impulse Biomedical

Customer profile

Segments4 records

Ideal customer profiles3 records

Impulse Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Impulse Biomedical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Maryland Department of CommercecoreStrategic or Co-development Partner · 5 May 2026Maryland Department of Commerce administers the Global Gateway Soft Landing Program that officially welcomed Impulse Biomedical. The program provides international companies support and resources to establish US presence, including access to facilities, capital, and partner advisors with industry knowledge. The state announced Impulse Biomed's medtech sector win at SelectUSA Investment Summit.
  • The LaunchPortcoreStrategic or Co-development Partner · 1 January 2026The LaunchPort is a Medtech manufacturing accelerator in Baltimore, MD where Impulse officially took up residence as part of its global expansion. The facility offers regulatory expertise, manufacturing infrastructure, and commercial partnership opportunities essential for US market entry. Impulse will explore manufacturing and sterilization partnerships through this accelerator.
  • University of Cape TowncoreStrategic or Co-development PartnerBoth ZiBiPen and Easy Squeezy were developed while founders Gokul Nair and Giancarlo Beukes completed Master's degrees in Biomedical Engineering at UCT. The Easy Squeezy was developed in collaboration with Dr Michael Levin, Head of Division of Asthma and Allergy at Red Cross Children's Hospital. Company maintains ongoing partnerships with UCT Med-Tech and University Tech Fund.
  • Allergy Foundation of South AfricaminorStrategic or Co-development PartnerPartner organization supporting allergy awareness and treatment access in South Africa, listed among collaborative successes on company website.
  • UCT Med-TechminorStrategic or Co-development PartnerUniversity of Cape Town medical technology initiative supporting biomedical innovation and commercialization, listed among collaborative successes.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Impulse Biomedical competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: AstraZeneca markets major respiratory brands (Symbicort, Breztri) and is investing heavily in respiratory biologics. Comparable as a broad respiratory incumbent whose inhaler portfolio is compatible with the Easy Squeezy device.
  • Teva Pharmaceutical Industries: Teva markets a generic EpiPen competitor as well as a broad respiratory portfolio (including ProAir inhalers compatible with Easy Squeezy). Operates in both of Impulse's core categories at scale with established distribution and regulatory infrastructure.
  • GlaxoSmithKline (GSK): GSK is a global leader in respiratory medicine (Ventolin, Advair, Trelegy) and would be a key inhaler manufacturer whose products are compatible with the Easy Squeezy. As a broad incumbent, GSK dwarfs Impulse in R&D and commercial reach, but its inhaler franchise is the natural target market for the Easy Squeezy sleeve.

Direct peers

  • Viatris (EpiPen): Viatris markets the EpiPen, the dominant single-use epinephrine auto-injector that Impulse's ZiBiPen directly competes against. Comparable on indication (anaphylaxis), patient population, and delivery modality, though Viatris operates at vastly greater scale and with a single-use (non-reloadable) architecture.
  • Kaleo (AUVI-Q): Kaleo manufactures AUVI-Q, a competing epinephrine auto-injector with voice-guided instructions. Direct competitor to ZiBiPen in the US anaphylaxis market, with comparable device form factor but differentiated by features (voice guidance vs. reloadable cartridge).
  • MannKind Corporation: MannKind develops inhaled drug delivery systems (Afrezza inhaler) and has a deep focus on innovative, patient-friendly inhaler technology. Comparable as a smaller specialty drug delivery company focused on inhalers, with similar disruptive positioning against large incumbents.
  • Amphastar Pharmaceuticals: Amphastar manufactures generic epinephrine auto-injectors (Symjepi) and competes with both EpiPen and ZiBiPen in the anaphylaxis space. Direct competitor on product category and indication, with focus on affordability similar to Impulse's positioning.

Emerging players

  • Insulet Corporation: Insulet's Omnipod is a reloadable, wearable drug delivery device (for insulin) that shares Impulse's architectural philosophy of reloadable cartridges replacing single-use devices. Comparable on the reloadable consumable model that anchors Impulse's value proposition.
  • ResMed (Propeller Health): ResMed's Propeller Health business offers digital inhaler sensors and companion software to improve asthma adherence and technique—addressing overlapping problems (poor inhaler technique in children and adults) as Impulse's Easy Squeezy, but via digital rather than mechanical intervention.

Others

  • Halozyme Therapeutics: Halozyme licenses its ENHANZE drug delivery platform to pharma partners for subcutaneous delivery of biologics. Comparable as an enabling drug delivery technology company in the broader medical device space, though focused on biologic formulations rather than emergency rescue injectors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Impulse Biomedical social profiles

Digital presence

Impulse Biomedical compliance and trust

Trust signal

Compliance4 records

Impulse Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Impulse Biomedical leadership team

Management profile

Number of profiles

Profiles12 records

Impulse Biomedical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Impulse Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impulse Biomedical

What does Impulse Biomedical do?

Impulse Biomedical designs, develops, and manufactures proprietary medical devices for asthma and allergy management. Its core products are the ZiBiPen, a patented reloadable epinephrine auto-injector for emergency anaphylaxis treatment that reduces cost by replacing only the drug cartridge, and the Easy Squeezy, an ergonomic reusable sleeve that fits over standard metered-dose inhalers to reduce activation force by 80%, enabling independent use by children and elderly patients.

Is Impulse Biomedical a public or private company?

Impulse Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Impulse Biomedical founded?

Impulse Biomedical was founded in 2017. It employs 11 to 50 people.

Where is Impulse Biomedical based?

Impulse Biomedical is headquartered in Cape Town, South Africa, in the Africa region.

How does Impulse Biomedical make money?

One revenue line is on record: medical Device Sales.

Who are Impulse Biomedical's main competitors?

Broad incumbents on record are AstraZeneca, Teva Pharmaceutical Industries and GlaxoSmithKline (GSK). Direct peers are Viatris (EpiPen), Kaleo (AUVI-Q), MannKind Corporation and Amphastar Pharmaceuticals. Emerging players are Insulet Corporation and ResMed (Propeller Health). Halozyme Therapeutics is listed as an others.

Does Impulse Biomedical have an API?

No public API is recorded for Impulse Biomedical.

What industry is Impulse Biomedical in?

Impulse Biomedical's product category is Medical Devices. Its primary akta.pro industry code is HLAHAIAB, Auto-Injectors (Disposable & Reusable), with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DisruptafricaSA’s Impulse Biomedical accepted into US expansion programmeSouth African startup Impulse Biomedical was accepted into the Maryland Global Gateway Soft Landing Programme, enabling its US expansion. The company, founded by Giancarlo Beukes and Gokul Nair, develops asthma and epinephrine devices and raised undisclosed funding last May. The programme provides facilities, capital, and partner advisors to support its US presence.Business Wire BlogImpulse Biomedical Announces Acceptance into the Maryland Global Gateway Soft Landing ProgramImpulse Biomedical, a Cape Town-based asthma and allergy company, was accepted into the Maryland Global Gateway Soft Landing Program on May 5th. The company, which developed ZiBiPen and Easy Squeezy devices, will use the program's resources to establish a US presence. It plans to focus on local operations and regulatory approval at The LaunchPort in Baltimore.citybizImpulse Biomed Joins Maryland Global Gateway Soft Landing ProgramGovernor Wes Moore announced that Impulse Biomed, a South African life sciences startup based in Cape Town, has joined the Maryland Global Gateway Soft Landing Program administered by the Maryland Department of Commerce, enabling the company to test the U.S. market. The company develops affordable medical devices including the Easy Squeezy accessibility device for asthma inhalers and the ZiBiPen reloadable autoinjector, and will be based at The LaunchPort medtech accelerator in Baltimore. The program offers six months of rent assistance, mentoring, and business registration support, and has previously supported 80 companies from 41 countries since its 2023 launch.ZawyaSouth African innovation in action: E Squared Investments backs medtech startup Impulse BiomedicalE Squared Investments and ANZA Capital invested in Cape Town medtech startup Impulse Biomedical, which develops asthma inhalers and a reloadable epinephrine auto-injector. The funding will support commercialization, regulatory pathways, and an international expansion ahead of a Series A raise.South Africa TodaySouth African Innovation in Action: E Squared Investments Backs MedTech Startup Impulse BiomedicalE Squared Investments and ANZA Capital invested in Cape Town-based MedTech startup Impulse Biomedical, which develops affordable medical devices like the Easy Squeezy inhaler and ZiBiPen auto-injector. The funding will support commercialization, regulatory pathways, and an international expansion ahead of a Series A raise.DisruptafricaSA med-tech startup Impulse Biomedical secures funding to commercialise, expandCape Town-based Impulse Biomedical raised an undisclosed amount of funding from E Squared Investments and ANZA Capital to commercialize its products and expand internationally. The startup, founded by Giancarlo Beukes and Gokul Nair, develops asthma and epinephrine devices, and the funding will support regulatory pathways and a planned Series A raise.EsquaredMedia Release: South African Innovation in Action – E Squared Investments Backs MedTech Startup, Impulse BiomedicalE Squared Investments and ANZA Capital invested in Cape Town-based MedTech startup Impulse Biomedical, which develops asthma inhalers and a reloadable epinephrine auto-injector. The funding will support commercialization, regulatory pathways, and an international expansion ahead of a Series A raise.University of Cape Town NewsUCT spin-off companies win inaugural Cape Chamber Innovation AwardThe Cape Chamber of Commerce and Industry awarded its inaugural Academic Innovation Award to two UCT spin-off companies, MariHealth Solutions and Impulse Biomedical. MariHealth focuses on aquaculture health management, while Impulse Biomedical develops medical devices like the Easy Squeezy inhaler attachment and ZiBiPen auto injector.University of Cape Town NewsUCT Spin-off Companies Win Inaugural Cape Chamber Innovation AwardMariHealth Solutions and Impulse Biomedical won the inaugural Cape Chamber of Commerce and Industry Innovation Award for Best University Spin-off Company. MariHealth focuses on aquaculture health using proteomics, while Impulse Biomedical develops medical devices like the Easy Squeezy inhaler attachment and ZiBiPen auto injector.LaunchafricaIMPULSE — Launch AfricaImpulse Biomedical, a Cape Town-based medical device start-up, is developing affordable healthcare technologies such as the ZiBiPen and Easy Squeezy to address anaphylaxis and asthma. The company has secured investment based on its proprietary IoT technology, registered patents, and a technical team led by co-founders Giancarlo Beukes and Gokul Nair. Their strategic focus is on ensuring accessibility to life-saving medical devices in developing and emerging markets.